Zobrazeno 1 - 10
of 264
pro vyhledávání: '"Hans M.G. Princen"'
Autor:
Alexandra K. Suchowerska, Geurt Stokman, James T. Palmer, Phillip A. Coghlan, Elsbet J. Pieterman, Nanda Keijzer, Gilles Lambert, Kevin Chemello, Ali K. Jaafar, Jasneet Parmar, Liping Yan, Yingtao Tong, Lin Mu, Hans M.G. Princen, James Bonnar, Benny J. Evison
Publikováno v:
Journal of Lipid Research, Vol 63, Iss 11, Pp 100293- (2022)
Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibits the clearance of low-density lipoprotein (LDL) cholesterol (LDL-C) from plasma by directly binding with the LDL receptor (LDLR) and sending the receptor for lysosomal degradation. As the
Externí odkaz:
https://doaj.org/article/a8352bacd19e43b9a0446b8b8c352c9b
Autor:
Marianne G. Pouwer, Elsbet J. Pieterman, Nicole Worms, Nanda Keijzer, J. Wouter Jukema, Jesper Gromada, Viktoria Gusarova, Hans M.G. Princen
Publikováno v:
Journal of Lipid Research, Vol 61, Iss 3, Pp 365-375 (2020)
Atherosclerosis-related CVD causes nearly 20 million deaths annually. Most patients are treated after plaques develop, so therapies must regress existing lesions. Current therapies reduce plaque volume, but targeting all apoB-containing lipoproteins
Externí odkaz:
https://doaj.org/article/ef5373475cbd46ad9e98e8368ae8f8d0
Autor:
Anita M. van denHoek, Elsbet J. Pieterman, José W. van derHoorn, Marta Iruarrizaga‐Lejarreta, Cristina Alonso, Lars Verschuren, Tore Skjæret, Hans M.G. Princen, David A. Fraser
Publikováno v:
Hepatology Communications, Vol 4, Iss 2, Pp 193-207 (2020)
Icosabutate is a structurally engineered eicosapentaenoic acid derivative under development for nonalcoholic steatohepatitis (NASH). In this study, we investigated the absorption and distribution properties of icosabutate in relation to liver targeti
Externí odkaz:
https://doaj.org/article/17635485619345adb907554abe0b690f
Publikováno v:
Toxicology Reports, Vol 3, Iss , Pp 306-309 (2016)
Externí odkaz:
https://doaj.org/article/4f6d4a02375e49018022be9fa0dbf95c
Autor:
Sam J.L. van der Tuin, Susan Kühnast, Jimmy F.P. Berbée, Lars Verschuren, Elsbet J. Pieterman, Louis M. Havekes, José W.A. van der Hoorn, Patrick C.N. Rensen, J. Wouter Jukema, Hans M.G. Princen, Ko Willems van Dijk, Yanan Wang
Publikováno v:
Journal of Lipid Research, Vol 56, Iss 11, Pp 2085-2093 (2015)
Recently, we showed in APOE*3-Leiden cholesteryl ester transfer protein (E3L.CETP) mice that anacetrapib attenuated atherosclerosis development by reducing (V)LDL cholesterol [(V)LDL-C] rather than by raising HDL cholesterol. Here, we investigated th
Externí odkaz:
https://doaj.org/article/703c44bd9c0c4c1b91d3e208489b298a
Autor:
Brandon Ason, José W.A. van der Hoorn, Joyce Chan, Edward Lee, Elsbet J. Pieterman, Kathy Khanh Nguyen, Mei Di, Susan Shetterly, Jie Tang, Wen-Chen Yeh, Margrit Schwarz, J. Wouter Jukema, Rob Scott, Scott M. Wasserman, Hans M.G. Princen, Simon Jackson
Publikováno v:
Journal of Lipid Research, Vol 55, Iss 11, Pp 2370-2379 (2014)
LDL cholesterol (LDL-C) contributes to coronary heart disease. Proprotein convertase subtilisin/kexin type 9 (PCSK9) increases LDL-C by inhibiting LDL-C clearance. The therapeutic potential for PCSK9 inhibitors is highlighted by the fact that PCSK9 l
Externí odkaz:
https://doaj.org/article/a47428822d15485fadea23f4fd960402
Autor:
Susan Kühnast, José W.A. van der Hoorn, Elsbet J. Pieterman, Anita M. van den Hoek, William J. Sasiela, Viktoria Gusarova, Anusch Peyman, Hans-Ludwig Schäfer, Uwe Schwahn, J. Wouter Jukema, Hans M.G. Princen
Publikováno v:
Journal of Lipid Research, Vol 55, Iss 10, Pp 2103-2112 (2014)
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition is a potential novel strategy for treatment of CVD. Alirocumab is a fully human PCSK9 monoclonal antibody in phase 3 clinical development. We evaluated the antiatherogenic potential of
Externí odkaz:
https://doaj.org/article/53e1f0f319af41358683cedf9dce15c4
Autor:
Caroline C. van der Hoogt, Willeke de Haan, Marit Westerterp, Menno Hoekstra, Geesje M. Dallinga-Thie, Johannes A. Romijn, Hans M.G. Princen, J. Wouter Jukema, Louis M. Havekes, Patrick C.N. Rensen
Publikováno v:
Journal of Lipid Research, Vol 48, Iss 8, Pp 1763-1771 (2007)
In addition to efficiently decreasing VLDL-triglycerides (TGs), fenofibrate increases HDL-cholesterol levels in humans. We investigated whether the fenofibrate-induced increase in HDL-cholesterol is dependent on the expression of the cholesteryl este
Externí odkaz:
https://doaj.org/article/f974ee9790bd4cc6b0f2a84d999b7a4d
Autor:
Nynke R. Koopen, Sabine M. Post, Henk Wolters, Rick Havinga, Frans Stellaard, Renze Boverhof, Folkert Kuipers, Hans M.G. Princen
Publikováno v:
Journal of Lipid Research, Vol 40, Iss 1, Pp 100-108 (1999)
Effects of 17α-ethinylestradiol (EE) on the neutral and acidic biosynthetic pathways of bile salt (BS) synthesis were evaluated in rats with an intact enterohepatic circulation and in rats with long-term bile diversion to induce BS synthesis. For th
Externí odkaz:
https://doaj.org/article/cc0fd8e0d4074301940fd93a7a8a4ed8
Autor:
Patrick C.N. Rensen, Geurt Stokman, Hans M.G. Princen, Michael Feigh, Marta Iruarrizaga-Lejarreta, José W.A. van der Hoorn, Ditte Denker Thorbekk, John J.P. Kastelein, Sanne Skovgård Veidal, Elsbet J. Pieterman, Lars Verschuren, David A. Fraser, Cristina Alonso, Scott L. Friedman, Brittany Basta, Tore Skjaeret, Anita M. van den Hoek, Jimmy F.P. Berbée
Publikováno v:
Liver International
Liver International, 40(11), 2860-2876. WILEY
Liver International, 40(11), 2860-2876. WILEY
Background & Aims While fibrosis stage predicts liver‐associated mortality, cardiovascular disease (CVD) is still the major overall cause of mortality in patients with NASH. Novel NASH drugs should thus ideally reduce both liver fibrosis and CVD. I